Grape King Bio Ltd. (1707) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grape King Bio Ltd. (1707:TWSE), powered by AI.

Current Price
$99.70
P/E Ratio
12.1
Market Cap
14.8B
Sector
Healthcare
What is the Grape King Bio Ltd. stock price forecast?

Grape King Bio Ltd. is currently trading at $99.70. View real-time AI analysis on Alpha Lenz.

What is Grape King Bio Ltd. insider trading activity?

View the latest insider trading data for Grape King Bio Ltd. on Alpha Lenz.

What is Grape King Bio Ltd.'s P/E ratio?

Grape King Bio Ltd.'s P/E ratio is 12.1.

Grape King Bio Ltd.

TWSE · 1707
NT$99.70-3.30(-3.20%)
Ask about Grape King Bio Ltd.'s future dividend policy...
Alpha Chat Insight

Grape King Bio Ltd. trades at a P/E of 12.1 (undervalued) with solid ROE of 11.9%. Operating margin of 20.9% indicates strong profitability.

Ask for details

Company Overview

Grape King Bio Ltd. is a notable player in the biotechnology and health food industry, primarily engaged in the production of probiotics, health supplements, and various functional foods. Its primary function is to innovate and manufacture products that enhance well-being by utilizing cutting-edge biotechnological advancements. The company's offerings are diversified across consumer health supplements, sports nutrition products, and specialty ingredients catering to diverse health needs and dietary preferences. Grape King Bio Ltd. serves a broad range of sectors, including food and beverage, pharmaceuticals, and health-focused retail industries, making its impact felt across multiple facets of consumer and health goods markets. With a strong presence in Taiwan and expanding reach in international markets, Grape King Bio Ltd. holds a significant role in driving forward advancements within the nutraceutical space, responding to the growing global demand for natural and effective health solutions.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

NT$14.77BMarket Cap
NT$10.25BRevenue
0.00Shares Out
0Employees

Margins

75.08%Gross
27.88%EBITDA
20.88%Operating
22.41%Pre-Tax
18.15%Net

Valuation

12.12P/E
1.43P/B
1.44EV/Sales
4.39EV/EBITDA
8.61P/FCF

Growth (CAGR)

-0.45%Rev 3Yr
2.26%Rev 5Yr
-5.70%Op Inc 3Yr
-1.46%Op Inc 5Yr
-4.99%Net Inc 3Yr
-0.36%Net Inc 5Yr

Returns

11.98%ROA
11.95%ROE
14.82%ROIC

Financial Health

NT$4.16BCash & Cash Equivalents
NT$-492.65MNet Debt
30.43%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Grape King Bio Ltd. (ticker: 1707) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $14.8B.

The current price is 99.7 with a P/E ratio of 12.12x and P/B of 1.43x.

ROE is 11.95% and operating margin is 20.88%. Annual revenue is $10.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Grape King Bio Ltd. (1707) Stock Forecast 2026 $99.70 — Price, Financials & Analyst Targets | Alpha Lenz